Inopem (Pemetrexed)

Inopem is an antifolate chemotherapy agent indicated for specific thoracic malignancies.

• Malignant pleural mesothelioma: improves overall survival when used in combination with cisplatin.
• Non‑small cell lung cancer (non‑squamous): provides disease control as first‑line therapy with cisplatin.
• Combination therapy with cisplatin: enhances antitumor efficacy in the above indications.

• Pemetrexed inhibits multiple folate‑dependent enzymes, including thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, disrupting purine and pyrimidine synthesis. This blockade impairs DNA and RNA production, leading to cell cycle arrest and apoptosis in rapidly dividing tumor cells.

Adverse reactions may occur with Inopem therapy.

Common Side Effects

• Fatigue: persistent tiredness during treatment.
• Nausea: feeling of sickness often requiring antiemetics.
• Vomiting: episodes of expulsion of stomach contents.
• Anemia: reduced red blood cell count causing weakness.
• Neutropenia: lowered neutrophil levels increasing infection risk.
• Rash: skin irritation or redness.

Serious or Rare Side Effects

• Severe allergic reaction: anaphylaxis requiring immediate medical attention.
• Pulmonary toxicity: breathing difficulties or interstitial lung disease.
• Renal failure: impaired kidney function needing monitoring.
• Cardiac toxicity: arrhythmias or reduced cardiac output.
• Febrile neutropenia: fever with low neutrophil count, a medical emergency.
• Thromboembolic events: blood clots in veins or arteries.

Prior to initiating Inopem, several safety considerations are recommended.

• Renal function: assess creatinine clearance before and during therapy.
• Hepatic function: monitor liver enzymes for potential toxicity.
• Hematologic status: perform regular complete blood counts.
• Folate supplementation: consider vitamin B12 and folic acid to reduce toxicity.
• Pregnancy: avoid use in pregnant women; discuss contraception with women of childbearing potential.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Pemetrexed may interact with other medicines, requiring vigilance.

Major Interactions (Avoid)

• Cisplatin: concurrent use increases risk of renal and hematologic toxicity.
• NSAIDs: may exacerbate renal impairment when combined.
• Folate antagonists (e.g., methotrexate): additive inhibition of folate pathways.

Moderate Interactions (Monitor Closely)

• Warfarin: monitor INR as pemetrexed can affect coagulation.
• Live vaccines: avoid administration during treatment due to immunosuppression.
• Certain antibiotics (e.g., penicillins): may influence blood count changes.